左西孟旦治疗心力衰竭的研究进展

www.yongyao.net　　2009-10-10 13:53:20　　来源：　　责任编辑：

分享到：

[ 参考文献]
[ 1 ] 　McMurray JJ , PfeiferMA. Heart failure [ J ]. Lancet, 2005, 365 ( 9474) : 1877-1889.
[ 2 ] 　Dec GW. Acute decompensated heart failure: the shrinking role of inotrop ic therapy[ J ]. J Am Coll Cardiol, 2005, 46 (1) : 65-67.
[ 3 ] 　Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic app roaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan[ J ] Eur JHeart Fail, 2003, 5 (1) : 13-221.
[ 4 ] 　Papp Z, Csapo K, Pollesello P, et al. Pharmacologicalmechanisms contributing to the clinical efficacy of levosimendan [ J ]. Cardiovasc Drug Rev, 2005, 23 ( 1) :71-98.
[ 5 ] 　GheorghiadeM, Teerlink JR,Mebazaa A. Pharmacology of new agents for the acute heart failure syndrome [ J ]. Am J Cardiol, 2005, 96 (6A) : 68G-73G.
[ 6 ] 　Ng TM. Levosimendan, a new calcium2sensitizing inotrope for heart failure [ J ].Pharmacotherapy, 2004, 24 (10) : 1366-1384.
[ 7 ] 　Mebazaa A, ErhardtL. Levosimendan: a new dual2action drug in the treatment of acute heart failure[ J ]. Int J Clin Pract, 2003, 57 (5) : 410-416.
[ 8 ] 　Cleland JG,N ikitin N,McGowan J. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure [ J ]. Expert Rev Cardiovasc Ther,2004, 2 (1) : 9-19.
[ 9 ] 　Kaheinen P, Pollesello P, Levijoki J. Effects of levosimendan and milrinone on oxygen consump tion in isolated guinea2p ig heart [ J ]. J Cardiovasc Pharmacol,2004, 43 (4) : 555-561.
[ 10 ] 　Paraskevaidis IA, Parissis JT, Th Kremastinos D. Anti2inflammatory and antiapop totic effects of levosimendan in decompensated heart failure: a novelmechanism of drug2induced imp rovement in contractile performance of the failing heart [ J ]. CurrMed Chem Cardiovasc HematolAgents, 2005, 3 (3) : 243-247.
[ 11 ] 　Kopustinskiene DM, Pollesello P, SarisNE. Potassium specific effects of levosimendan on heart mitochondria [ J ]. B iochem Pharmacol, 2004, 68 ( 5 ) : 807-812.
[ 12 ] 　Pataricza J , Krassoi I, Hohn J , et al. Functional role of potassium channels in the vasodilatingmechanism of levosimendan in porcine isolated coronary artery[ J ]. Cardiovasc Drugs Ther, 2003, 17 (2) : 115-121.
[ 13 ] 　Grossini E, Caimmi PP,Molinari C. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized p ig [ J ]. J Cardiovasc Pharmacol, 2005, 46 (3) : 333-342.
[ 14 ] 　Kyrzopoulos S,Adamopoulos S, Parissis JT, et al. Levosimendan reduces p lasmaB2type natriuretic pep tide and interleukin 6, and imp roves central hemodynamics in severe heart failure patients[ J ]. Int J Cardiol, 2005, 99 (3) : 409-413.
[ 15 ] 　Avgeropoulou C,Andreadou I,Markantonis2Kyroudis S, et al. The Ca2 + 2sensitizer levosimendan imp rove oxidative damage, BNP and p ro2inflammatory cytokine level in patientswith advanced decompensated heart failure in comparison to dobutamine [ J ]. Eur J Heart Fail, 2005, 7 (5) : 882-887.
[ 16 ] 　KivikkoM,Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure [ J ]. Curr Pharm Des, 2005, 11 (4) : 435-455.
[ 17 ] 　Takahashi R, TalukderMA, EndohM. Inotrop ic effects of OR21896, an activemetabolite of levosimendan, on canine ventricularmyocardium [ J ]. Eur J Pharmacol, 2000, 400 (1) : 103-112.
[ 18 ] 　NieminenMS, Akkila J , Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure [ J ]. J Am Coll Cardiol, 2000, 36 (6) : 1903-1912.
[ 19 ] 　SlawskyMT, ColucciWS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patientswith severe heart failure: Study Investigators[ J ]. Circulation, 2000, 102 (18) : 2222-2227.
[ 20 ] 　Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in sever low2output heart failure ( the L IDOstudy) : a randomised double2blind trial [ J ]. Lancet, 2002, 360 ( 9328 ) : 196-202.
[ 21 ] 　Moiseyev VS, Poder P,AndrejevsN, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patientswith left ventricular failure due to an acute myocardial infarction: a randomized, p lacebo2controlled, double2blind study(RUSSLAN) [ J ]. Eur Heart J , 2002, 23 (18) : 1422-21432.
[ 22 ] 　Cleland JG, Ghosh J , Freemantle N, et al. Clinical trials update and cumulative meta2analyses from the American College of Cardiology:WATCH, SCD2HeFT,D INAM IT, CASINO, INSP IRE, STRATUS2US, R IO2L ip ids and cardiac resynchronisation therapy in heart failure [ J ]. Eur J Heart Fail, 2004, 6 ( 4) : 501-508.
[ 23 ] 　Cleland JG, TakalaA,ApajasaloM, et al. Intravenous levosimendan treatment is cost2effective compared with dobutamine in severe low2output heart failure: an analysis based on the international L IDO trial [ J ]. Eur J Heart Fail, 2003, 5(1) : 101-108.
[ 24 ] 　Mclean AS, Huang ST,NalonsM, et al. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B2type natriuretic pep tide [ J ]. J Cardiovasc Pharmacol, 2005, 46(9) : 830-835.
[ 25 ] 　Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPA IR2AM I, ASTAM I, JEL IS,MEGA, REV IVEⅡ, SURV IVE and PROACTIVE [ J ]. Eur J Heart Fail, 2006, 8 (1) : 105-110.
[ 26 ] 　L illeberg J , Yloneh V, Lehtonen L, et al. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies [ J ]. Scand Cardiovasc J , 2004, 38 (2) : 80-84.